Oral Dexmedetomidine effect on pain management in pediatric ALL patients under blood sampling: A randomized, double blind, clinical trial
Phase 3
Recruiting
- Conditions
- Acute lymphoblastic leukemia.Acute lymphoblastic leukemiaC91.0
- Registration Number
- IRCT20190804044429N11
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Children from 2 to 16 years old
ALL patients
In the phase of maintenance treatment according to the COG protocol
ASA score 1-2
Admitted to the hematology and oncology department of Bou Ali Sina Hospital
Candidate for blood sampling
Exclusion Criteria
Congenital heart disease
Mentally disabled
Use of psychiatric medications
Taking beta blockers
History of arrhythmias
Recent respiratory infection
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie oral dexmedetomidine's analgesic effects in pediatric ALL patients during blood sampling?
How does oral dexmedetomidine compare to standard analgesics like acetaminophen for procedural pain in ALL pediatric oncology?
Are there biomarkers associated with differential response to alpha-2 adrenergic agonists in C91.0 ALL patients undergoing invasive procedures?
What adverse event profiles are reported for oral dexmedetomidine in pediatric leukemia populations and how are they managed?
What combination analgesic strategies involving dexmedetomidine are being explored for pediatric hematologic malignancies?